MAP Pharmaceuticals , Nasdaq: MAPP
Developing inhalable drugs to treat migraine and pediatric asthma.
Industry: Health Care
First Day Return: +11.3%
Industry: Health Care
| IPO Data | |
|---|---|
| IPO File Date | 06/18/2007 |
| Offer Price | $12.00 |
| Price Range $14.00 - $16.00 | |
| Offer Shares (mm) | 5.0 |
| Deal Size ($mm) | $60 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | 10/04/2007 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $60 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Mountain View, CA, United States |
| Founded | 2003 |
| Employees at IPO | n/a |
| Website www.mappharma.com | |
MAP Pharmaceuticals (MAPP) Performance
